317 related articles for article (PubMed ID: 17431029)
41. Pharmacokinetics, disposition, and metabolism of bicifadine in the mouse, rat, and monkey.
Musick TJ; Gohdes M; Duffy A; Erickson DA; Krieter PA
Drug Metab Dispos; 2008 Feb; 36(2):241-51. PubMed ID: 17991767
[TBL] [Abstract][Full Text] [Related]
42. Metabolism, pharmacokinetics, and excretion of the 5-hydroxytryptamine1b receptor antagonist elzasonan in humans.
Kamel A; Obach RS; Colizza K; Wang W; O'Connell TN; Coelho RV; Kelley RM; Schildknegt K
Drug Metab Dispos; 2010 Nov; 38(11):1984-99. PubMed ID: 20668248
[TBL] [Abstract][Full Text] [Related]
43. Absorption, metabolism, and excretion of [
Ye YE; Woodward CN; Narasimhan NI
Cancer Chemother Pharmacol; 2017 Mar; 79(3):507-518. PubMed ID: 28184964
[TBL] [Abstract][Full Text] [Related]
44. Excretion and metabolism of the antihypertensive agent, RWJ-26240 (McN-5691) in dogs.
Wu WN; Masucci JA; Caldwell GW; Carson JR
Drug Metab Dispos; 1998 Feb; 26(2):115-25. PubMed ID: 9456297
[TBL] [Abstract][Full Text] [Related]
45. Absorption, distribution, metabolism, and excretion of ticagrelor in healthy subjects.
Teng R; Oliver S; Hayes MA; Butler K
Drug Metab Dispos; 2010 Sep; 38(9):1514-21. PubMed ID: 20551239
[TBL] [Abstract][Full Text] [Related]
46. Absorption and disposition of the sphingosine 1-phosphate receptor modulator fingolimod (FTY720) in healthy volunteers: a case of xenobiotic biotransformation following endogenous metabolic pathways.
Zollinger M; Gschwind HP; Jin Y; Sayer C; Zécri F; Hartmann S
Drug Metab Dispos; 2011 Feb; 39(2):199-207. PubMed ID: 21045200
[TBL] [Abstract][Full Text] [Related]
47. Pharmacokinetics, disposition, and metabolism of bicifadine in humans.
Krieter PA; Gohdes M; Musick TJ; Duncanson FP; Bridson WE
Drug Metab Dispos; 2008 Feb; 36(2):252-9. PubMed ID: 17991768
[TBL] [Abstract][Full Text] [Related]
48. Metabolism and pharmacokinetics of indacaterol in humans.
Kagan M; Dain J; Peng L; Reynolds C
Drug Metab Dispos; 2012 Sep; 40(9):1712-22. PubMed ID: 22648561
[TBL] [Abstract][Full Text] [Related]
49. Metabolic disposition of casopitant, a potent neurokinin-1 receptor antagonist, in mice, rats, and dogs.
Miraglia L; Pagliarusco S; Bordini E; Martinucci S; Pellegatti M
Drug Metab Dispos; 2010 Oct; 38(10):1876-91. PubMed ID: 20622044
[TBL] [Abstract][Full Text] [Related]
50. Metabolism and excretion of [(14)C]celecoxib in healthy male volunteers.
Paulson SK; Hribar JD; Liu NW; Hajdu E; Bible RH; Piergies A; Karim A
Drug Metab Dispos; 2000 Mar; 28(3):308-14. PubMed ID: 10681375
[TBL] [Abstract][Full Text] [Related]
51. Metabolism, pharmacokinetics and excretion of a potent tachykinin NK1 receptor antagonist (CP-122,721) in rat: characterization of a novel oxidative pathway.
Kamel A; Davis J; Potchoiba MJ; Prakash C
Xenobiotica; 2006; 36(2-3):235-58. PubMed ID: 16702114
[TBL] [Abstract][Full Text] [Related]
52. Excretion, Mass Balance, and Metabolism of [
Katyayan K; Yi P; Monk S; Cassidy K
Drug Metab Dispos; 2020 Aug; 48(8):698-707. PubMed ID: 32499340
[TBL] [Abstract][Full Text] [Related]
53. Metabolism and disposition of a potent and selective GABA-Aalpha2/3 receptor agonist in healthy male volunteers.
Polsky-Fisher SL; Vickers S; Cui D; Subramanian R; Arison BH; Agrawal NG; Goel TV; Vessey LK; Murphy MG; Lasseter KC; Simpson RC; Vega JM; Rodrigues AD
Drug Metab Dispos; 2006 Jun; 34(6):1004-11. PubMed ID: 16510541
[TBL] [Abstract][Full Text] [Related]
54. The disposition of prasugrel, a novel thienopyridine, in humans.
Farid NA; Smith RL; Gillespie TA; Rash TJ; Blair PE; Kurihara A; Goldberg MJ
Drug Metab Dispos; 2007 Jul; 35(7):1096-104. PubMed ID: 17403916
[TBL] [Abstract][Full Text] [Related]
55. Pharmacokinetics, metabolism, and excretion of [14C]axitinib, a vascular endothelial growth factor receptor tyrosine kinase inhibitor, in humans.
Smith BJ; Pithavala Y; Bu HZ; Kang P; Hee B; Deese AJ; Pool WF; Klamerus KJ; Wu EY; Dalvie DK
Drug Metab Dispos; 2014 May; 42(5):918-31. PubMed ID: 24608633
[TBL] [Abstract][Full Text] [Related]
56. Metabolism and pharmacokinetics of naronapride (ATI-7505), a serotonin 5-HT(4) receptor agonist for gastrointestinal motility disorders.
Bowersox SS; Lightning LK; Rao S; Palme M; Ellis D; Coleman R; Davies AM; Kumaraswamy P; Druzgala P
Drug Metab Dispos; 2011 Jul; 39(7):1170-80. PubMed ID: 21447732
[TBL] [Abstract][Full Text] [Related]
57. Metabolism and excretion of a novel antianxiety drug candidate, CP-93,393, in Long Evans rats. Differentiation of regioisomeric glucuronides by LC/MS/MS.
Prakash C; Soliman V
Drug Metab Dispos; 1997 Nov; 25(11):1288-97. PubMed ID: 9351906
[TBL] [Abstract][Full Text] [Related]
58. Excretion and metabolism of lersivirine (5-{[3,5-diethyl-1-(2-hydroxyethyl)(3,5-14C2)-1H-pyrazol-4-yl]oxy}benzene-1,3-dicarbonitrile), a next-generation non-nucleoside reverse transcriptase inhibitor, after administration of [14C]Lersivirine to healthy volunteers.
Vourvahis M; Gleave M; Nedderman AN; Hyland R; Gardner I; Howard M; Kempshall S; Collins C; LaBadie R
Drug Metab Dispos; 2010 May; 38(5):789-800. PubMed ID: 20124396
[TBL] [Abstract][Full Text] [Related]
59. The neurokinin 1 receptor antagonist, ezlopitant, reduces appetitive responding for sucrose and ethanol.
Steensland P; Simms JA; Nielsen CK; Holgate J; Bito-Onon JJ; Bartlett SE
PLoS One; 2010 Sep; 5(9):. PubMed ID: 20824145
[TBL] [Abstract][Full Text] [Related]
60. Metabolism and disposition of the metabotropic glutamate receptor 5 antagonist (mGluR5) mavoglurant (AFQ056) in healthy subjects.
Walles M; Wolf T; Jin Y; Ritzau M; Leuthold LA; Krauser J; Gschwind HP; Carcache D; Kittelmann M; Ocwieja M; Ufer M; Woessner R; Chakraborty A; Swart P
Drug Metab Dispos; 2013 Sep; 41(9):1626-41. PubMed ID: 23775850
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
